Washington, D.C.–based watchdog and consumer-advocacy nonprofit
A U.S. FDA advisory panel is evaluating seven peptide injections for potential compounding by licensed pharmacies. The panel's votes and the FDA's stance reflect ongoing debates about safety, efficacy, and industry influence amid rising wellness interest in peptides.
The FDA has moved to close the GRAS loophole by requiring safety data for new ingredients and creating a public inventory. A parallel step defines ultraprocessed foods to help future regulation. Officials say the measures increase transparency but are not expected to alter consumer diets immediately.